Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TLR4 | O00206 | 5/20 | 0.43 |
| ▸ | CA2 | P00918 | 9/20 | 0.40 |
| ▸ | CA12 | O43570 | 8/20 | 0.40 |
| ▸ | CA1 | P00915 | 8/20 | 0.40 |
| ▸ | CA9 | Q16790 | 8/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 8/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ANTXR2 | P58335 | 2/20 | 0.36 |
| ▸ | LY96 | Q9Y6Y9 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20582014 | 0.92 | MAPT (0.49) | MAPTTLR4CA2CA12CA1 | |
| SCHEMBL16500346 | 0.92 | MAPT (0.49) | MAPTTLR4CA2CA12CA1 | |
| SCHEMBL3334421 | 0.92 | MAPT (0.49) | MAPTTLR4CA2CA12CA1 | |
| SCHEMBL13621251 | 0.92 | MAPT (0.49) | MAPTTLR4CA2CA12CA1 | |
| SCHEMBL16500298 | 0.92 | MAPT (0.49) | MAPTTLR4CA2CA12CA1 | |
| SCHEMBL3336043 | 0.92 | MAPT (0.49) | MAPTTLR4CA2CA12CA1 | |
| SCHEMBL19079629 | 0.91 | MAPT (0.47) | MAPTTLR4CA2CA12CA1 | |
| SCHEMBL22107783 | 0.88 | MAPT (0.46) | MAPTTLR4CA2CA12CA1 | |
| SCHEMBL22034448 | 0.88 | MAPT (0.40) | MAPTTLR4CA2CA12CA1 | |
| SCHEMBL5958120 | 0.87 | TLR4 (0.53) | MAPTTLR4LY96 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220041641-A1 | QUATERNARY AMMONIUM SALTS AS INHIBITORS OF TRIMETHYLAMINE PRODUCTION | SENDA BIOSCIENCES INC (US) | 2022-02-10 | — | — | US | disclosed |
| EP-3891751-A1 | QUATERNARY AMMONIUM SALTS AS INHIBITORS OF TRIMETHYLAMINE PRODUCTION | Senda Biosciences, Inc. (US) | 2021-10-13 | — | — | EP | disclosed |
| WO-2020118238-A1 | QUATERNARY AMMONIUM SALTS AS INHIBITORS OF TRIMETHYLAMINE PRODUCTION | KINTAI THERAPEUTICS, INC. (US) | 2020-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220041641-A1 | QUATERNARY AMMONIUM SALTS AS INHIBITORS OF TRIMETHYLAMINE PRODUCTION | SLC10A2, SLC10A1, BCAT2 | MAPT 136/4885TLR4 1722/4885CA2 284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.